Tissue Repair & Cytoprotective Research Peptides
BPC-157
Last reviewed: 2026-11-19
Evidence status & limitations
Animal experiments and small uncontrolled human reports cannot establish structural healing or long-term safety.
Regulatory status
No FDA-approved human medicine for this exact identity was established in this review. Investigational research is not approval.
Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.
WADA prohibited status: current list and contextKnown risks & open questions
Reliable adverse-event rates are unknown; FDA identifies immune-reaction, impurity and identity concerns.
Key sources
Identity and editorial screen completed November 19, 2026. Previously checked primary references retained; this is not an exhaustive clinical review.
Related compounds
- Thymosin beta-4
Same scientific class · A 43-amino-acid chain. · Late-stage human trials
- Thymosin beta-4 fragment (17–23)
Same scientific class · A seven-amino-acid sequence, LKKTETQ, corresponding to residues 17–23 of thymosin beta-4. · Cell/lab studies only